ASH 2023 | What’s on the horizon for patients with Richter’s transformation?
Adam Kittai, MD, Ohio State University, Columbus, OH, gives an overview of the latest advancements in therapies for Richter’s transformation (RT) and how this space might evolve going forward. He mentions combination therapy with a PD-1 inhibitor plus zanubrutinib, the bispecific antibodies mosunetuzumab and epcoritamab, and the non-covalent BTK inhibitor (BTKi) pirtobrutinib. Dr Kittai highlights that the last couple of years have been exciting for the treatment of RT, with more on the horizon. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Eli Lilly, BeiGene, AstraZeneca, AbbVie, Janssen, KITE, BMS
Research Funding,: BeiGene, AstraZeneca
Speakers Bureau: BeiGene
